Search results

28 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Proposed [GID-HST10034] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Givosiran for treating acute hepatic porphyria [ID1549]

In development [GID-HST10035] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Proposed [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Avalglucosidase alfa for treating Pompe disease [ID3737]

Proposed [GID-HST10030] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Proposed [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Proposed [GID-HST10043] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Proposed [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Clostridioides difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 23 July 2021

Type

Antimicrobial prescribing guideline

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development

Filter (7 in use)

Type 2 selected

Status 3 selected

Last updated

Guidance programme 2 selected

28 results

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Stye: antimicrobial prescribing

Blepharitis: antimicrobial prescribing

Velmanase alfa for treating alpha-mannosidosis [ID800]

Human alpha1-proteinase inhibitor for treating emphysema ID856

Givosiran for treating acute hepatic porphyria [ID1549]

Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

Afamelanotide for treating erythropoietic protoporphyria [ID927]

Avalglucosidase alfa for treating Pompe disease [ID3737]

Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

OTL-200 for treating metachromatic leukodystrophy [ID1666]

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

Skin abscess: antimicrobial prescribing

Conjunctivitis: antimicrobial prescribing

Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Clostridioides difficile infection: antimicrobial prescribing

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]